News ASCO 25: Braftovi shows "unprecedented" survival gain Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in the BREAKWATER trial, setting up full FDA approval.
News Summit shrugs off survival miss with its VEGF bispecific Summit Therapeutics thinks new data on PD-1xVEGF drug ivonescimab may support FDA approval, despite a survival miss.
News Astellas adds to claudin clout with $1.3bn+ Evopoint deal Astellas was the first company to bring a drug against the claudin target CLDN18.2 to market, and has now added another to its cancer pipeline.
News MSD and Daiichi Sankyo pull HER3-DXd's FDA filing MSD and Daiichi Sankyo suffer another setback with their HER3 programme ahead of a crucial data readout at ASCO.
News Eisai says patent win blocks Lenvima generic to 2036 Eisai has won a lawsuit blocking FDA approval of Shilpa's generic of cancer blockbuster Lenvima until 2036, although the verdict could go to appeal.
News UK cancer centre launches AI-powered detection drive The Royal Marsden NHS Foundation Trust has joined forces with two private-sector companies on AI models to detect cancer and guide treatment choices.
News GBL joins CVC in €10.7bn takeover bid for Recordati A consortium of investors has made a €10.7bn offer to take Italian pharma Recordati private, but some analysts are sceptical the deal will go through.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
